„In April 2020, we opened up a new facility for gene therapy in Orth an der Donau in Austria, namely Evotec Gene Therapy (Evotec GT). In this way, we complemented a further important building block in our active substance research platform. In order to be an ideal partner for research and development of new medicines, we have to technologically encompass all possible active ingredient types such as small molecules, biologics and also gene therapies. For this reason, our gene therapy site in Austria comprises an important lane on our development highway designed to support our long-term growth path."
Dr. Werner Lanthaler, Chief Executive Officer of Evotec SE
With its workforce of more than 3,400 employees, the company offers its customers around the world high-quality, independent and integrated solutions in active substance research, from target to clinical development. An experienced team of gene therapy experts will work at the new R&D site in Lower Austria. At the same time, the new facility has entered into a long-term research alliance with Takeda in order to support a growing number of gene therapy research programmes.